NCT04481412Phase 2/3Completed
Topical Cetirizine in Androgenetic Alopecia in Females
The Role of Cetirizine in Androgenetic Alopecia in Females
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2/3
- Sponsor
- Cairo University
- Participants (registry)
- 66
- Start
- July 2020
- Primary completion
- November 2021
- Study completion
- November 2021
- Last registry update
- February 2023
- Countries
- Egypt
Conditions studied: Androgenetic Alopecia
Interventions: Topical cetirizine, Cetirizine 1%, Placebo, 96% ethanol, Topical minoxidil, Minoxidil 5%
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.